BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16740753)

  • 21. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
    Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H
    J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HDAC6 expression is correlated with better survival in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Omoto Y; Ando Y; Mita K; Hamaguchi M; Hayashi S; Iwase H
    Clin Cancer Res; 2004 Oct; 10(20):6962-8. PubMed ID: 15501975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
    Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
    Jiang WG; Douglas-Jones AG; Mansel RE
    Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Hara Y; Kobayashi S; Iwase H
    Breast Cancer Res Treat; 2005 Nov; 94(1):11-6. PubMed ID: 16172792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
    J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.
    Płuciennik E; Kusińska R; Potemski P; Kubiak R; Kordek R; Bednarek AK
    Eur J Surg Oncol; 2006 Mar; 32(2):153-7. PubMed ID: 16360296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
    Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
    Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
    Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
    Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
    Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant expression of cyclin E in low-risk node negative breast cancer.
    Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML
    Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.
    Koga T; Tokunaga E; Sumiyoshi Y; Oki E; Oda S; Takahashi I; Kakeji Y; Baba H; Maehara Y
    Hepatogastroenterology; 2008; 55(84):1131-5. PubMed ID: 18705345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer.
    Jotsuka T; Okumura Y; Nakano S; Nitta H; Sato T; Miyachi M; Suzumura K; Yamashita J
    Surgery; 2004 Apr; 135(4):419-26. PubMed ID: 15041966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.